Skip to main content
Signal8

Aurinia Pharmaceuticals Inc. (AUPH)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPHHealthcare
Pre+0.24%$16.50
Close$16.46+1.54%AH$16.46+0.24%since
Mkt Cap$2.21B
Float107.31M
O/S134M
Inst Own59.8%
SI7.3%
Dilution
Aurinia Pharmaceuticals Inc. logoNASDAQ:AUPHPre$16.50+0.24%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202616.2516.5716.1616.461,275,138
Nov 5, 202617.2117.2916.1316.211,139,541
Nov 4, 202616.8817.4016.5617.111,477,029
Nov 3, 202616.1516.7316.1316.561,183,769
Nov 2, 202616.6716.7115.9516.141,611,138
Oct 30, 202616.7617.0416.4816.65960,844
Oct 29, 202617.4417.5817.1017.21744,724
Oct 28, 202616.8417.3816.8417.36625,991
Oct 27, 202616.9817.2716.9617.25494,480
Oct 26, 202616.9817.1616.9117.04794,704
Oct 23, 202617.2717.3116.8116.86649,243
Oct 22, 202617.0017.4116.8417.33780,506
Oct 21, 202616.7317.0116.6316.90783,237
Oct 20, 202616.6016.8216.5616.74593,683
Oct 19, 202616.5416.7416.4516.49552,185
Oct 16, 202616.8116.8116.3516.51737,548
Oct 15, 202616.8417.3016.7116.731,034,774
Oct 14, 202616.2416.8216.1116.611,225,703
Oct 13, 202616.4616.5816.2116.361,137,741
Oct 12, 202616.6116.7016.4816.55654,768
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
11
HOLD
4
SELL
0
TOTAL15
Insider Trades
InsiderTypeShares
Robertson Stephen P. profile photoRobertson Stephen P.Sale11.9K
Robertson Stephen P. profile photoRobertson Stephen P.Sale21.0K
Johnson Craig A profile photoJohnson Craig AGrant/Award23.9K
Bailey Jeffrey Allen profile photoBailey Jeffrey AllenGrant/Award23.9K
Goetz Kathleen profile photoGoetz KathleenGrant/Award23.9K
Nova Tina Susan profile photoNova Tina SusanGrant/Award23.9K
Shareholders
59.8%
Institutional
(290)
3.1%
Insiderⓘ
(12)
4.4%
5%+ Owners
(1)
32.7%
Unattributed (incl. retail)ⓘ
Institutional59.8%
Insider3.1%
5%+ Beneficial4.4%
Unattributed (incl. retail)32.7%
Sources: 13F, Form 4, 13D/13GO/S: 134.0M · as of 29 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies.

Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally.

The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd.

The firm's main corporate office is located in Victoria, Canada.

Key Metrics
Market Cap$2.21B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership59.75%

based on 134.00M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryCACA
IPO DateSep 3, 2014
Shares Outstanding134.00M
Authorized Shares
Float107.31M
52-Week Range
$13.52$19.25
$16.46(51st percentile)
Volume
Average Daily Volume922.84K
1.28M today vs 922.84K avg(+38%)

30d Avg

922.84K

60d Avg

875.51K

90d Avg

907.49K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...